Table 1:
SCA3 (n = 17) | SCA6 (n = 17) | Difference of Mean SCA3 vs SCA6a | |
---|---|---|---|
Age (yr) | 49.8 ± 11.5 (27–67) | 65.8 ± 6.5 (52–75) | P = .008b |
Sex (M/F) | 10:7 | 11:6 | |
Disease duration (yr) | 6.4 ± 4.8 (0–18) | 8.9 ± 5.7 (1–23) | N.S. |
Age at onset (yr) | 43.4 ± 12.3 (19–62) | 55.6 ± 8.7 (41–67) | P = .004b |
CAG repeat length | 68.7 ± 3.5 (58–73) | 21.6 ± 0.7 (21–22) | N.A. |
ICARS | 34.7 ± 10.8 (17–60) | 30.6 ± 10.9 (15–46) | N.S. |
I) Posture and gait | 11.0 ± 7.8 (2–29) | 9.0 ± 5.2 (3–23) | P = .043c |
II) Kinetic functions | 13.0 ± 4.8 (2–24) | 13.0 ± 6.1 (5–32) | N.S. |
III) Speech | 3.0 ± 1.5 (0–5) | 3.0 ± 1.6 (0–6) | N.S. |
IV) Oculomotor | 4.0 ± 1.5 (0–6) | 5.0 ± 1.2 (2–6) | N.S. |
Statistically significant differences between the SCA3 and SCA6 patient groups under consideration of the disease duration; analysis of variance (GLM model) with disease duration as a covariable.
Significant with P< .01.
Significant with P < .05.